seem to be specific to PCH, demonstrating the usefulness of HRCT scanning for diagnosis of this disease. Other previously reported CT findings of the disease include increased soft tissue density of the mediastinum, mediastinal and hilar lymphadenopathy, but such findings were absent in our case.

Possible explanations for the stable condition of our case over a long period are either that it was a chance discovery of an early phase of the disease by HRCT scanning or that PCH has separate subtypes with differing speeds of progression. Wider use of HRCT scanning and more extensive understanding of PCH would resolve this issue in the future.

The authors thank Professor Rubin M Tuder (Department of Pathology-Surgical Pathology Laboratory, University of Colorado Health Sciences Center) and Professor Takesaburo Ogata (Center for Medical Sciences, Ibaraki Prefectural University of Health Sciences) for their pathological review of the case. This work was supported by funding from the Ministry of Education of Japan.

3 Wagnerova CT, Bectstra A, Spijker J. Capillary hemangioma
5 Vevaina JR, Mark EJ. Thoracic hemangiomatosis masquer-
hemangiomatosis: report of a case and review of the litera-
7 Dufour B, Maitre S, Humbert M, et al. High-resolution CT of
the chest in four patients with pulmonary capillary
hemangiomatosis or pulmonary venoocclusive disease.
Furthermore, the effect of vibration on the developing brain is uncertain. We do not know whether the vibration will compromise the cerebral haemodynamic stability resulting in adverse neurological outcomes, especially in premature neonates who transmit vibration more efficaciously because of less body mass and fat compared with term neonates. Moreover, the combined effects of vibratory stress and environmental noise may contribute to hearing loss.\(^1\)

Although no definitive vibration disease has been recognised in neonates, we have demonstrated the inadvertent exposure of neonates to excessive vibration. Research is required to examine the significance of HFV induced vibration and to reduce the vibration without compromising its effectiveness in critically ill neonates.

**National survey of detention and TB**

In England and Wales the power to detain individuals with tuberculosis who pose a threat to public health lies principally in sections 37 and 38 of the Public Health Act 1984.\(^3\) Section 37 authorises a local authority officer to remove an individual to a suitable hospital and section 38 authorises a local authority officer to detain an individual for tuberculosis.\(^2\)

Increases in the incidence of tuberculosis outbreaks in healthcare settings and the scourge of drug resistant and multidrug resistant strains have, over the past decade, perhaps concentrated the minds of clinicians and public health physicians on ensuring that patients comply with treatment, and this may be playing a part. Elsewhere, notably in New York but also in Europe, consideration of the legal and ethical aspects of contemporary control measures has resulted in legislative amendments to public health laws which have enabled public health authorities to detain, for prolonged periods, patients with tuberculosis who will not or cannot comply with treatment.\(^4\) Failures in sources to facilitate patients’ adherence to treatment, particularly in London, may also be contributing to the use of more restrictive measures by the authorities.\(^5\) An alternative explanation may be that, because of drug resistance and associated HIV infection, the treatment of tuberculosis is becoming increasingly complex, demanding greater commitment from patients and clinicians. This survey suggests that there is a need to monitor formally, in an ongoing fashion, trends in the issuance of detention orders for individuals with tuberculosis.

I thank the consultants in communicable disease control in England and Wales for assisting with this research and the Communicable Disease Surveillance Centre for providing the data on pulmonary tuberculosis notifications.

R J COKER

London School of Hygiene & Tropical Medicine, ECOHOST, London WC1E 7HT, UK

Richard.coker@lshtm.ac.uk


**Churg-Strauss syndrome**

We read the review of Churg-Strauss syndrome (CSS) by Conron and Beynon\(^1\) with interest. The studies they quote are all reported from tertiary or national referral centres with inevitable referral bias. We have published our experience of 23 patients with CSS—the only study from a district general hospital which may be more representative of the natural history of this systemic vasculitis in

---

**Figure 1 Section 38 detention orders controlled by pulmonary tuberculosis notification rate and health authority response rate in England and Wales, 1994–9.**

<table>
<thead>
<tr>
<th>Year</th>
<th>Detention orders issued (standardised)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>5</td>
</tr>
<tr>
<td>1995</td>
<td>4</td>
</tr>
<tr>
<td>1996</td>
<td>3</td>
</tr>
<tr>
<td>1997</td>
<td>2</td>
</tr>
<tr>
<td>1998</td>
<td>1</td>
</tr>
<tr>
<td>1999</td>
<td>0</td>
</tr>
</tbody>
</table>

---
the general population. The mean age of onset was 57 years, significantly older than the 40 years reported in patients from tertiary centres and quoted by Conron and Beynon. We found there was a slight male preponderance (65%), also shown in many previous studies. The commonest sites of extrarespiratory involvement were, in descending frequency, the nervous system, joints and muscles, kidneys, skin, heart, and gastrointestinal tract. Involvement of the gastrointestinal tract occurred in only 30% and abdominal pain was uncommon. Cardiac involvement occurred in 44% and was the cause of death in two. Renal involvement, although occurring in nearly half the patients, was usually mild and none had severe renal failure.

The mean age of onset of asthma was 50 years and, although not reported, the asthma was not usually troublesome or severe when the symptoms of CF first occurred. Indeed, very few patients were on oral steroids for their asthma at that time. Very rarely, patients present with CSS who do not have asthma. In our series there was one such patient who satisfied in the original histological features of Churg and Strauss.

We found that the criteria developed by Lanham et al were the most useful, particularly an eosinophil count of >1.5 × 10⁹/l. While this is arbitrary, only one of our patients had a level below this and that was 1.4 × 10⁹/l.

**Acute rib fracture pain in CF**

Recent papers in *Thorax* have described the high prevalence of low bone mineral density (BMD) in individuals with cystic fibrosis; these patients are at increased risk of fractures. Rib fracture pain can often be difficult to treat, despite standard analgesia such as non-steroidal anti-inflammatory drugs and opiates. Rib pain can impair sputum clearance and lead to an exacerbation of CF pulmonary disease. There are reports that calcitonin can relieve bone pain for patients with osteolytic metastases and ostearthritic vertebral fractures. Recently, we have successfully used subcutaneous calcitonin for the treatment of rib fracture pain in two patients with CF.

A 25 year old woman fractured two ribs when she was crushed in the crowd at a rock concert and a 28 year old man fractured ribs following a bout of coughing. Both patients had CF related low BMD with DEXA Z scores at the lumbar spine of −2.5 and −3.6, respectively. They had been taking long term oral prednisolone at a dose of 10 mg per day. Both patients had continuous uncontrolled pain from their fracture sites despite regular oral analgesics. The female patient was taking paracetamol 1 g qds and morphine sulphate modified release 30 mg bd; the male patient was taking paracetamol 1 g qds and ibuprofen 600 mg tds. Both patients were given courses of antibiotics as the pain was leading to an exacerbation of their CF lung disease. Subcutaneous calcitonin 100 μg was given in a dose of 50 units once daily. The pain completely resolved within 48 hours in both cases, and the patients were able to mobilise, perform sputum clearance, the other analgesics were withdrawn, and the chest exacerbations resolved. The calcitonin injections were continued for a total of 7 days, then stopped without recurrence of any pain. Neither patient experienced any side effects from the calcitonin.

Although calcitonin is involved in the regulation of bone turnover, the mechanism of its analgesic action is unknown. It reduces bone resorption and bone formation, but may also have central analgesic effects. Conversely, intravenous bisphosphonates, given to improve bone density, were associated with severe bone pain in individuals with CF. Pain control was possible in patients with CF and rib fractures if adequate sputum clearance is to be achieved and an acute deterioration in lung disease avoided. Calcitonin should be considered as an analgesic in this situation. Such intervention may reduce morbidity and mortality associated with rib fractures in this group of patients.

**Endothelin in acute exacerbations of COPD**

We read with interest the article by Roland et al on endothelin-1 (ET-1) levels in exacerbations of chronic obstructive pulmonary disease (COPD). The authors found increased sputum levels of ET-1 in patients with COPD during an exacerbation, which was reflected by a smaller rise in venous ET-1 levels.

We have recently performed a study to evaluate pulmonary and renal ET levels in nine consecutive COPD patients during an acute exacerbation. ET was detected by radioimmunoassay in venous and arterial blood as well as in a timed urine specimen. For each subject the ratio of systemic arterial/mixed venous ET1 levels (ir-ETart/ir-ETven) was evaluated as an index of pulmonary clearance/production of the peptide. The ir-ETart/ir-ETven ratio was calculated in patients with COPD examined both during an exacerbation and at recovery (0.75 (0.12) and 0.77 (0.13), respectively). Otherwise, the calculated ir-ETart/ir-ETven ratio in patients with COPD was significantly lower than that calculated in patients with acute pulmonary embolism, a condition in which pulmonary endothelial dysfunction is likely to occur. A significant difference was found with respect to a 24 hour ir-ET urinary excretion between COPD patients during an exacerbation and at recovery (142.1 (12.8) ng/24 hours and 89.0 (15.1) ng/24 hours, respectively).

Further, renal clearance of ET was higher in COPD patients during an exacerbation (29.2 (5.2) ml/min) than at recovery (17.5 (3.9) ml/min), suggesting an increase in renal ET production in patients with COPD during an exacerbation and the absence of significant changes in ET1 circulating levels.

We therefore think that increased sputum ET1 levels found in patients with COPD during an acute exacerbation could represent a true increase in local ET production, with a firm relationship between venous and sputum ET1 levels not being established.

Correspondence to: M Maniscalco  
M SOFIA  
MANISCALCO Pulmonary and Vascular Unit, A O Monaldi, University “Federico II”  
Napoli, Italy
who received prophylaxis from birth had one or more isolates of Staphylococcus aureus over a 3 year period. There was also evidence at 2 years that less time was spent in hospital in the prophylaxis group. The number of children receiving prophylaxis who had one or more isolates of P aeruginosa over a 3 year period was half that of the control group who had intermittent antibiotic treatment only. This was not, however, statistically significant (Peto odds ratio 0.54, 95% confidence interval 0.23 to 1.26).

The steering group of the North American cephalixin trial have indicated that its results will be published soon (Eliezer Nussbaum, personal communication). However, until there is published evidence from at least one properly designed randomised controlled trial, the proposal that prophylaxis encourages pulmonary infection with P aeruginosa remains entirely speculative.

A SMYTH
Department of Paediatrics, Nottingham City Hospital, Nottingham NG5 1PB, UK
D. Smyth@compuserve.com

S WALTERS
Department of Public Health and Epidemiology, University of Birmingham, Birmingham B15 2TT, UK
s.walters@bham.ac.uk


AUTHOR’S REPLY I thank Drs Smyth and Walters for their comments concerning the issue of whether antistaphylococcal prophylaxis leads to a higher risk of colonisation with Pseudomonas aeruginosa in patients with cystic fibrosis. I share their concern as to the lack of definitive data supporting this notion and, indeed, tried to illustrate this in my article by stating “There is some evidence that it may be associated . . . “. I would suggest, however, that the authors’ evidence of a lack of association is equally thin—to quote a multicentre trial whose methodology was presented as an abstract some 9 years ago but whose results do not appear to have ever been published in a peer reviewed journal is certainly not basing one’s evidence on hard evidence based facts. I did not mention the review by Smyth and Walters’ in my own paper as I submitted my review some 18 months before theirs had been published; however, the authors did not include in their own letter discussion of the recent paper by Ratjen et al using data from the German CF database which included 639 patients, all under 18 years of age and P aeruginosa negative prior to entry in the study. 48.2% of the patients received continuous antistaphylococcal treatment, 40.4% received intermittent antibiotic treatment, and 11.4% received no antibiotic treatment. While the rate at which patients acquired positive respiratory cultures for Staphylococcus aureus was significantly lower in the group receiving continuous antistaphyloccocal antibiotic treatment than in those receiving no such treatment, patients receiving continuous antistaphyloccocal antibiotic treatment had a significantly higher rate of P aeruginosa acquisition than patients receiving only intermittent or no antibiotic treatment. This difference was especially apparent for children under the age of 6 years. The authors concluded that “continuous therapy with antistaphyloccocal antibiotics directed against Staph aureus increases the risk of colonisation with P aeruginosa”.

This interesting study I believe again supports my original statement that “there is some evidence that it (continuous antistaphyloccocal antibiotic therapy) may be associated with earlier acquisition of P aeruginosa”. I would suggest, however, that antistaphyloccocal prophylaxis directed against Staph aureus may be associated with earlier acquisition of P aeruginosa.

P ROBINSON
Cystic Fibrosis Unit, Department of Respiratory Medicine, Royal Children’s Hospital, Melbourne Australia 3052
philro@cryptic.rch.unimelb.edu.au

NOTICES

The Dr H M (Bill) Foreman Memorial Fund

The Trustees of the above fund invite applications for grants relating to study in respiratory disease and allied fields. Limited funds are available for registered medical practitioners to assist in travelling to countries other than their own to study respiratory disease, and also for support for clinical research abroad.

The HMF Fund has been able to fund two medical student projects in the last 18 months, one on TB in Malaysia and one on TB in Ghana, and has awarded three travel grants to study the following aspects of respiratory disease: Dr Veronica White (London) to study TB in Bangladesh; Dr R T Jagoe (Newcastle upon Tyne) to study the ATP-ubiquitin-proteasome proteolytic system in Boston, USA; Dr J S Parmar (Cambridge) to study cell motility in Toronto; and a grant to Dr Anne Chang (Brisbane) to study the relationship between cough and asthma.

Intending applicants should write for further details to Dr Brian H Davies, Llandough Hospital, Penarth, Vale of Glamorgan CF64 2AA, UK.

Pharmacology of Asthma

A course on the “Pharmacology of Asthma” organised by Professor Peter Barnes will be held at the Imperial College School of Medicine at the National Heart & Lung Institute in collaboration with the Royal Brompton Hospital, Dovehouse Street, London SW3 6LY, UK on 26–29 November 2001. The course is suitable for physicians or scientists with an interest in the pharmacology and therapeutics of asthma. For further information please contact the Postgraduate Education Centre, Imperial College School of Medicine at the National Heart & Lung Institute, Dovehouse Street, London SW3 6LY. Telephone: 020 7351 8172. Fax: 020 7351 8246. Email: shortcourses.nhli@ic.ac.uk

Respiratory Medicine

A conference on Respiratory Medicine will be held at the Royal College of Physicians of Edinburgh on 26 October 2001. For further information contact Ms Eileen Straw, Symposium Coordinator. Telephone 0131 225 7324. Fax 0131 220 4593. Email: e.strawn@rcpe.ac.uk. Website: www.rcpe.ac.uk

CORRECTION

In the “Statement on Malignant Mesothelioma in the United Kingdom” by the British Thoracic Society Standards of Care Committee which appeared in the April issue of Thorax (2001;56:250–65), the telephone number given for the National Mesothelioma Helpline on page 264 is incorrect. The correct number is 0113 206 6466. The email address is mavisro@ulth.northy.nhs.uk
National survey of detention and TB

R J COKER

Thorax 2001 56: 818
doi: 10.1136/thorax.56.10.818

Updated information and services can be found at:
http://thorax.bmj.com/content/56/10/818.1

These include:

References
This article cites 4 articles, 1 of which you can access for free at:
http://thorax.bmj.com/content/56/10/818.1#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/